Substance / Medication

Masoprocol

Overview

Active Ingredient
masoprocol
RxNorm CUI
227239

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

4 trials linked to this intervention

4
Total Trials
0
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Clinical features, histology, and treatment outcomes of granular parakeratosis: a systematic review.
Ip Ken Hiu-Kan, Li Angela · Int J Dermatol · 2022
PMID: 35094385Meta-AnalysisFull text (PMC)
Contemporary management of keratosis obturans: a systematic review.
Harounian J A, Patel V A, Isildak H · J Laryngol Otol · 2021
PMID: 34348811Meta-Analysis
Association between teat-end hyperkeratosis and mastitis in dairy cows: A systematic review.
Pantoja J C F, Correia L B N, Rossi R S et al. · J Dairy Sci · 2020
PMID: 31759610Meta-Analysis
Loricrin downregulation and epithelial-related disorders: a systematic review.
Catunda Raisa, Rekhi Umar, Clark Danielle et al. · J Dtsch Dermatol Ges · 2019
PMID: 31846220Meta-Analysis
A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa.
Frew John W, Hawkes Jason E, Krueger James G · F1000Res · 2018
PMID: 31281635Meta-AnalysisFull text (PMC)
WITHDRAWN: Interventions for photodamaged skin.
Samuel Miny, Brooke Rebecca, Hollis Sally et al. · Cochrane Database Syst Rev · 2015
PMID: 26035235Meta-AnalysisFull text (PMC)
Biologic markers of sun exposure and melanoma risk in women: pooled case-control analysis.
Olsen Catherine M, Zens Michael S, Green Adele C et al. · Int J Cancer · 2011
PMID: 20857492Meta-AnalysisFull text (PMC)
Masoprocol: a promising candidate for targeting insulin resistance by inhibiting resistin with optimal druglikeness Potentials: anapproach.
Al-Shuhaib Mohammed Baqur S, Alam Sarfaraz, Khan Salman Ali et al. · J Biomol Struct Dyn · 2024
PMID: 37671847Other
Masoprocol decreases rat lipolytic activity by decreasing the phosphorylation of HSL.
Gowri M S, Azhar R K, Kraemer F B et al. · Am J Physiol Endocrinol Metab · 2000
PMID: 10950827Preclinical
Masoprocol decreases serum triglyceride concentrations in rats with fructose-induced hypertriglyceridemia.
Scribner K A, Gadbois T M, Gowri M et al. · Metabolism · 2000
PMID: 11016888Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Masoprocol (substance)
SNOMED CT
108933006
UMLS CUI
C0733397
RxNorm CUI
227239

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
4
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.